Tempus AI (TEM)
Health Care · health technology / precision medicine · NASDAQ
Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers.
What Tempus AI does
Tempus AI is a technology company that uses artificial intelligence to improve precision medicine by unlocking data from clinical and molecular records. The company operates two primary segments: Diagnostics, which provides genomic and clinical testing services, and Data and Applications, which offers AI-enabled platforms and data sets to support research and clinical decision-making.
Themes: AI healthcare, precision medicine, genomics, oncology informatics, clinical diagnostics
Fundamentals
- Price$72.69 as of 2026-08-21 close
- Market cap$9.8B as of 2026-08-24
- 1-year return-5.2% 2025-08-21 close $76.71 → 2026-08-21 close $72.69
- P/En/a negative earnings
- Net margin-17.8% as of 2026-08-24
- Gross margin+64.0% as of 2026-08-24
- ROE-54.7% as of 2026-08-24
- Debt / equity3.06 as of 2026-08-24
- Revenue growth (YoY)+50.4% as of 2026-08-24
- Revenue CAGR (3y)+58.3% SEC XBRL
- Beta2.36 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How TEM compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TEM is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
48.8 #875 of 1,704 scored · #156 of 240 in Health Care
Volume and participation 98th: trading volume is running unusually high — about 2.7× its 30-day average, a sign of heightened interest; trend 77th: the price is 26% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 23rd: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which TEM reported a dividend payment is FY2024, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2024 ratio would not describe TEM today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2024) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How Tempus AI looks technically
Tempus AI (TEM) is trading 26.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 143 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70). It just made a new 20-day high, its first since 2025-12-11, pushing above its recent trading range. It is 30.3% below its highest point of the past year. Trading volume is running unusually high — about 2.7× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 26.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +26.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $52.66 | $52.66 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $57.36 | $57.36 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 143 trading days ago — a "death cross", a bearish long-term signal | 143 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 26.7% above | +26.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 27.6 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70) | 75.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($44.80 to $72.96) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $104.32 | $104.32 |
|---|---|---|
| From the 52-week high | it is 30.3% below its 52-week high (its highest price of the past year) | -30.3% |
| Above the 52-week low | it is 78.3% above its 52-week low (its lowest price of the past year) | +78.3% |
| Below the 52-week high | it is 30.3% below its highest point of the past year | 30.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2025-12-11, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2025-12-11, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $104.32 (set on 2025-10-09) | $104.32 |
| Given back of the 52-week move | over the past year its closes ranged ($41.55 to $103.25), and it has recovered around half of its fall from last year’s high — 50% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $79.68 to $81.66. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 50.5% |
| From the all-time high | it is 30.3% below its all-time high | -30.3% |
| Nearest price level | it is trading 1.4% above a support level at $71.69 — a price it turned at twice since 2025-05-14, most recently on 2025-09-02. Since 2024-08-21 it has 11 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $22.89 (set on 2024-06-25) | $22.89 |
| Above the all-time low | it is 217.6% above its all-time low | +217.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.41 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.41 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.31 and $67.37 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.31 – $51.34 – $67.37 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges above its 200-day average price (26.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.7× its 30-day average, a sign of heightened interest | 2.74× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.6% |
|---|---|---|
| Open gap | it gapped 13.4% above the previous close 2 sessions ago and has not traded back through the level it left behind at 49.36 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +13.4% |
| Gap filled | a 3.0% gap down opened on 2026-08-18 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +47.26% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 46.1 percentage points (the stock gained 48.4% while the market gained 2.3%) | +46.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 53.3 percentage points (the stock gained 56.4% while the market gained 3.1%) | +53.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 13.5 percentage points (the stock gained 24.5% while the market gained 11.1%) | +13.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.7 percentage points (the stock lost 5.2% while the market gained 20.5%) | -25.7% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 29% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.6% of the share price. | +29.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $54.07 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +34.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 26% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $57.51 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +26.4% |
Price levels it has turned at before
TEM last closed at $72.69 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $71.69 | Support | 1.4% below the last close | turned there twice · 2025-05-14 to 2025-09-02 |
| $74.71 | Resistance | 2.8% above the last close | turned there twice · 2025-06-16 to 2025-09-25 |
| $68.85 | Support | 5.3% below the last close | turned there twice · 2024-12-02 to 2025-05-27 |
| $79.41 | Resistance | 9.2% above the last close | turned there three times · 2024-11-12 to 2025-12-08 |
| $63.16 | Support | 13.1% below the last close | turned there twice · 2025-06-23 to 2026-07-01 |
| $91.25 | Resistance | 25.5% above the last close | turned there twice · 2025-02-14 to 2025-09-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.19 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$62.64 range $35.00 – $100.00; median $59.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TEM
- Consensus EPS estimate-$0.07269 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and potential inability to achieve or maintain profitability.","Significant reliance on Data and Applications segment growth and data licensing revenue.","Intense competition in the clinical diagnostics and healthcare data analytics markets."]
What changed in the latest 10-Q
AI-assisted comparison of TEM's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing)
- Product line restructuring: two product lines now listed as 'Diagnostics and Data and applications' instead of three ('Genomics, Data and AI Applications')
- Diagnostics product line description includes 'other anatomic and molecular pathology testing' with removal of 'state-of-the-art' modifier
- Data commercialization products expanded to include 'Insights, Trials, Next and Algos' (versus prior 'Insights and Trials')
- Revenue figures for three months ended March 31, 2026 and 2025: $348.1 million and $255.7 million respectively
- Net loss figures for three months ended March 31, 2026 and 2025: $125.9 million and $68.0 million respectively
- Adjusted EBITDA figures for three months ended March 31, 2026 and 2025: $(2.8) million and $(16.2) million respectively
- New section on Strategic Collaborations describing AstraZeneca and Pathos agreements from April 2025, including Foundation Model development and $35 million fee
- Removed:
- Reference to Annual Report on Form 10-K for year ended December 31, 2024 (older filing)
- Three product line structure (Genomics, Data and AI Applications)
- 'Genomics' product line name
- 'AI Applications' product line name
- 'state-of-the-art' descriptor for laboratories
- Revenue and net loss figures for three and nine months ended September 30, 2025 and 2024
- Adjusted EBITDA figures for three and nine months ended September 30, 2025 and 2024
- Convertible Senior Notes section describing July 3, 2025 offering of $750 million notes
- Reworded:
- Product line reorganization: 'three product lines: Genomics, Data and AI Applications' changed to 'two product lines: Diagnostics and Data and applications'
- 'Data and Services products, Insights and Trials' changed to products including 'Insights, Trials, Next and Algos'
- 'AI Applications' product line name changed to 'Applications' product line
- Notes:
- Older filing text is truncated at end of GAAP definition; newer filing text is truncated mid-sentence in Strategic Collaborations section
- Comparison reflects different quarterly periods (Q1 2026 vs Q3 2025) with different reporting periods and comparable years
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 42 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 20 sells ($13M) — 4 selling insiders
- Last 90 days0 buys · 42 sells ($33M) — 6 selling insiders
- Last 180 days0 buys · 52 sells ($45M) — 9 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TEM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for TEM from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding TEM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 24,026,739
- Reported value $1,086,489,127
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TEM had 33,229,165 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for TEM because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 33,229,165
- Prior settlement (shares) 30,360,084
- Reported change 9.45%
- Days to cover (reported) 5.86
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Illumina (ILMN)
- Foundation Medicine (Roche)
- Veracyte (VCYT)
- Natera (NTRA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TEM vs…
Tempus AI is found in…
Frequently asked questions
What does Tempus AI (TEM) do?
Tempus AI is a technology company that uses artificial intelligence to improve precision medicine by unlocking data from clinical and molecular records. The company operates two primary segments: Diagnostics, which provides genomic and clinical testing services, and Data and Applications, which offers AI-enabled platforms and data sets to support research and clinical decision-making.
What sector is Tempus AI (TEM) in?
Tempus AI (TEM) is classified in the Health Care sector. Its industry is health technology / precision medicine. It trades on NASDAQ.
Who are Tempus AI's (TEM) competitors?
Notable peers of Tempus AI (TEM) include Guardant Health, Exact Sciences, Illumina, Foundation Medicine (Roche) and Veracyte. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in TEM?
Yes — we hold 2 matched STOCK Act disclosures for TEM from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Tempus AI (TEM) overbought or oversold right now?
Tempus AI (TEM) is currently in overbought territory (its 14-day RSI is 75, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TEM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.